Skye Bioscience (SKYE) vs Xenetic Biosciences (XBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xenetic Biosciences is the larger company by market cap ($3.3 million vs $3.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SKYE | XBIO |
|---|---|---|
| Share price | $0.70 | $1.40 |
| Market cap | $3.10M | $3.28M |
| 1-day change | -11.03% | -9.09% |
| EPS (TTM) | $-7.56 | $-1.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.98M |
| Revenue growth (YoY) | — | +19.04% |
| Net income (latest FY) | $-55.92M | $-2.68M |
| Operating margin | — | -95.23% |
| Net margin | — | -90.07% |
| 52-week high | $11.04 | $4.94 |
| 52-week low | $0.484 | $1.25 |
| Distance from 52-week high | -93.66% | -71.65% |
| Analyst consensus | none | — |
| Avg. price target upside | +9614.29% | — |
| Average volume | 88.19K | 73.30K |
| Shares outstanding | 4.42M | 2.34M |
| Employees | 2 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Xenetic Biosciences
XBIO stock →Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
SKYE vs XBIO FAQ
Which is bigger, Skye Bioscience or Xenetic Biosciences?
Xenetic Biosciences (XBIO) is larger, with a market capitalization of $3.28M compared with $3.10M for Skye Bioscience (SKYE).
Are Skye Bioscience and Xenetic Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.